证券记录 · 已归档季度
NVS
Novartis AG · Healthcare · Drug Manufacturers - General
13被追踪持有人
—Δ持有人
33.92M持有股份
$3.61B报告持仓市值
+0新建仓位
−0清仓
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q2 2024
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q2 2026 | 125 | +1 | 102.39M | $16.04B | +8 | −7 |
| Q1 2026 | 126 | +1 | 113.27M | $17.29B | +8 | −7 |
| Q4 2025 | 124 | +1 | 102.45M | $14.13B | +1 | — |
| Q3 2025 | 20 | -1 | 49.48M | $6.35B | — | −1 |
| Q2 2025 | 18 | 0 | 41.97M | $5.08B | +2 | −2 |
| Q1 2025 | 16 | +1 | 41.02M | $4.58B | +1 | — |
| Q4 2024 | 15 | +1 | 35.01M | $3.41B | +1 | — |
| Q3 2024 | 13 | 0 | 33.66M | $3.89B | — | — |
| Q2 2024 | 13 | — | 33.92M | $3.61B | — | — |
持有人 · Q2 2024
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Dodge & Cox ✦ | 12.24M | — | $1.30B | 0.8% | n/c | 1 | SEC ↗ |
| 2 | PRIMECAP Management ✦ | 12.18M | — | $1.30B | 0.9% | n/c | 1 | SEC ↗ |
| 3 | Wellington Management ✦ | 4.38M | — | $466.79M | 0.1% | n/c | 1 | SEC ↗ |
| 4 | Wellington Management ✦ | 4.38M | — | $466.79M | 0.1% | n/c | 1 | SEC ↗ |
| 5 | Wellington Management ✦ | 4.38M | — | $466.79M | 0.1% | n/c | 1 | SEC ↗ |
| 6 | Wellington Management ✦ | 4.38M | — | $466.79M | 0.1% | n/c | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 4.38M | — | $466.79M | 0.1% | n/c | 1 | SEC ↗ |
| 8 | Wellington Management ✦ | 4.38M | — | $466.79M | 0.1% | n/c | 1 | SEC ↗ |
| 9 | Wellington Management ✦ | 4.38M | — | $466.79M | 0.1% | n/c | 1 | SEC ↗ |
| 10 | Wellington Management ✦ | 4.38M | — | $466.79M | 0.1% | n/c | 1 | SEC ↗ |
| 11 | Renaissance Technologies ✦ | 2.50M | — | $266.13M | 0.5% | n/c | 1 | SEC ↗ |
| 12 | Fisher Asset Management ✦ | 1.47M | — | $156.94M | 0.1% | n/c | 1 | SEC ↗ |
| 13 | Arrowstreet Capital ✦ | 630.71K | — | $67.14M | 0.1% | n/c | 1 | SEC ↗ |
| 14 | Citadel Advisors ✦ | 246.56K | — | $26.25M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | Two Sigma Investments ✦ | 156.41K | — | $16.65M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | Tweedy, Browne ✦ | 87.61K | — | $9.33M | 0.4% | n/c | 1 | SEC ↗ |
| 17 | AQR Capital Management ✦ | 9.70K | — | $1.03M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | AQR Capital Management ✦ | 9.70K | — | $1.03M | 0.0% | n/c | 1 | SEC ↗ |
| 19 | Millennium Management ✦ | 8.86K | — | $943,555 | 0.0% | n/c | 1 | SEC ↗ |
| 20 | T. Rowe Price ✦ | 7.09K | — | $755,000 | 0.0% | n/c | 1 | SEC ↗ |
| 21 | T. Rowe Price ✦ | 7.09K | — | $755,000 | 0.0% | n/c | 1 | SEC ↗ |
| 22 | D. E. Shaw & Co. ✦ | 2.84K | — | $301,921 | 0.0% | n/c | 1 | SEC ↗ |
"持仓权重"= 该持仓占该管理人已申报13F股权价值的比例——即信念度衡量指标。✦ = 精选管理人。
新增买入方
| 本季度无新增被追踪买入方。 |
已清仓
| 本季度无被追踪的退出仓位。 |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 2 持有人, 1.31M 股份, $431.09M 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
该证券的被追踪持有人最常同时持有的其他证券——基于共同持有计数，而非基本面关联。
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q2 2024 ·
方法论 ·
通过API获取此数据